Shionogi & Co (JP:4507) has released an update.
Shionogi & Co. announced successful results from its Phase 3 SCORPIO-PEP trial, demonstrating that the oral antiviral ensitrelvir effectively prevents symptomatic COVID-19 post-exposure. This significant advancement positions ensitrelvir as a potential preventative treatment option, highlighting Shionogi’s continued innovation in addressing global health challenges.
For further insights into JP:4507 stock, check out TipRanks’ Stock Analysis page.
